SCHEMBL4646906

SCHEMBL4646906

O=C1CN(c2cc(Cc3ccccc3)ccc2OCc2ccccc2)S(=O)(=O)N1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 7/20 0.53
SNRNP200 O75643 1/20 0.40
SLC6A4 P31645 2/20 0.38
HTR1A P08908 1/20 0.38
SLC6A2 P23975 1/20 0.38
SLC6A3 Q01959 1/20 0.38
FFAR4 Q5NUL3 1/20 0.36
PDE4A P27815 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4C Q08493 1/20 0.36
PDE4D Q08499 1/20 0.36
FFAR1 O14842 1/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAOA P21397 3/20 0.36
MAOB P27338 3/20 0.36
FOLH1 Q04609 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL646919 0.91 PTPN1 (0.47) PTPN1SNRNP200SLC6A4HTR1ASLC6A2
SCHEMBL4643306 0.86 PTPN1 (0.53) PTPN1SLC6A4RAB9ASMN1; SMN2PTPN2
SCHEMBL4643501 0.84 PTPN1 (0.62) PTPN1SNRNP200SLC6A4HTR1ASLC6A2
SCHEMBL4647040 0.84 PTPN1 (0.50) PTPN1SNRNP200SLC6A4HTR1ASLC6A2
Potassium SCHEMBL4647048 0.84 PTPN1 (0.50) PTPN1SNRNP200SLC6A4HTR1ASLC6A2
SCHEMBL4646708 0.82 PTPN1 (0.60) PTPN1FFAR4
SCHEMBL4648902 0.82 PTPN1 (0.45) PTPN1SNRNP200FFAR4NPC1MAPT
SCHEMBL647267 0.81 MRGPRX4 (0.43) PTPN1NPC1MAPTRAB9ASMN1; SMN2
SCHEMBL2935327 0.81 PTPN1 (0.56) PTPN1PTPN2
SCHEMBL4646366 0.81 PTPN1 (0.61) PTPN1SNRNP200SLC6A4HTR1ASLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080293782-A1 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors NOVARTIS AG (CH) 2008-11-27 US disclosed
EP-1960377-A1 l , l , 3-TRI0X0-l , 2 , 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS Novartis AG (CH) 2008-08-27 EP disclosed
WO-2007067614-A1 l, l, 3-TRI0X0-l, 2, 5-THIADIAZ0LIDINES AND THEIR USE AS PTP-ASES INHIBITORS NOVARTIS AG (CH) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293782-A1 1,1,3-Trioxo-1,2,5-Thiadiazolidines and Their Use as Ptp-Ases Inhibitors PTPRS, IRS1, PTPMT1 PTPN1 10/4885SNRNP200 3957/4885SLC6A4 3509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.